Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.76 USD | -3.34% | -0.53% | -36.49% |
04-04 | Morgan Stanley Initiates Coverage on Mural Oncology With Overweight Rating, $13 Price Target | MT |
01-08 | Mural Oncology plc Announces Enhancements to Late-Stage Clinical Trials | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 63.63M 86.61M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 156M 213M | Net cash position 2025 * | 196M 267M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 119 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.82% |
1 day | -3.34% | ||
1 week | -0.53% | ||
Current month | +1.62% | ||
3 months | -23.73% | ||
6 months | -23.89% | ||
Current year | -36.49% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 3.76 | -3.34% | 103,388 |
24-05-16 | 3.89 | +1.04% | 89,934 |
24-05-15 | 3.85 | -1.79% | 121,159 |
24-05-14 | 3.92 | +4.53% | 92,807 |
24-05-13 | 3.75 | -0.79% | 53,705 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.49% | 65.83M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- MURA Stock